Author: admin

Chronic Brain Damage Market Revenue to Expand Significantly by 2032, States DelveInsight Report | Hope Biosciences, Innopharm LLC, SanBio, Rohto Pharma, Teva Branded Pharma

The Key Chronic Brain Damage Companies in the market include – Hope Biosciences, Innopharm LLC, SanBio, Inc., Bundang CHA Hospital, Teva Branded Pharmaceutical, Neurocrine Biosciences, Jazz Pharmaceuticals, Avid Radiopharmaceuticals, Rohto Pharmaceutical, Merz Pharmaceuticals, and others.

 

DelveInsight’s “Chronic Brain Damage Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chronic Brain Damage, historical and forecasted epidemiology as well as the Chronic Brain Damage market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

The latest healthcare forecast report provides an in-depth analysis of Chronic Brain Damage, offering comprehensive insights into the Chronic Brain Damage revenue trends, prevalence, and treatment landscape. The report delves into key Chronic Brain Damage statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Chronic Brain Damage therapies. Additionally, we cover the landscape of Chronic Brain Damage clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Chronic Brain Damage treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Chronic Brain Damage space.

 

To Know in detail about the Chronic Brain Damage market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Brain Damage Market Forecast

 

Some of the key facts of the Chronic Brain Damage Market Report:

  • The Chronic Brain Damage market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

  • In October 2024, Nexalin Technology collaborated with the University of California, San Diego, to initiate a clinical trial assessing its neurostimulation device, the Gen-3 Halo headset, as a home-based treatment for mild traumatic brain injury. This sham-controlled study aims to examine the device’s impact on brain activity and symptom relief in veterans with mild traumatic brain injury within virtual clinic settings. The trial plans to enroll up to 60 participants.

  • In July 2024, SanBio Co., Ltd. (TOKYO:4592) announced that on July 31, 2024, it received conditional and time-limited marketing approval in Japan for its human somatic stem cell-processed product, AKUUGO® (vandefitemcel) suspension for intracranial implantation. AKUUGO® is approved for the treatment of chronic motor paralysis caused by traumatic brain injury.

  • Millions of people worldwide suffer from chronic brain damage due to various causes such as trauma, stroke, or neurodegenerative diseases.

  • Chronic brain damage is often a result of moderate to severe TBI, affecting around 69 million people annually worldwide.

  • Conditions like Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis contribute significantly to chronic brain damage cases.

  • Strokes are a leading cause, with approximately 15 million stroke cases globally each year, many resulting in long-term brain damage.

  • The risk increases with age, especially in individuals above 65 years, due to neurodegenerative processes.

  • Men are at a higher risk due to increased exposure to injuries, but women have higher mortality rates after brain damage-related conditions.

  • Contact sports contribute significantly, with 5-10% of athletes experiencing repetitive brain trauma, increasing the risk of Chronic Traumatic Encephalopathy (CTE).

  • Key Chronic Brain Damage Companies: Hope Biosciences, Innopharm LLC, SanBio, Inc., Bundang CHA Hospital, Teva Branded Pharmaceutical, Neurocrine Biosciences, Jazz Pharmaceuticals, Avid Radiopharmaceuticals, Rohto Pharmaceutical, Merz Pharmaceuticals, and others

  • Key Chronic Brain Damage Therapies: Autologous HB-adMSCs, BOTOX®, SB623 cells, Erythropoietin, TEV-50717, Valbenazine, Sativex, florbetapir F 18, UDI-001, NT 201, and others

  • The Chronic Brain Damage market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Brain Damage pipeline products will significantly revolutionize the Chronic Brain Damage market dynamics.

 

Chronic Brain Damage Overview

Chronic Brain Damage refers to long-term or permanent injury to the brain caused by factors such as trauma, stroke, neurodegenerative diseases, infections, or prolonged substance abuse. It can lead to cognitive impairment, memory loss, difficulty in motor functions, behavioral changes, and emotional instability. Conditions like chronic traumatic encephalopathy (CTE) and hypoxic brain injury are examples of chronic brain damage. While some symptoms can be managed with rehabilitation, medications, and therapy, the damage is often irreversible, affecting a person’s overall quality of life.

 

Get a Free sample for the Chronic Brain Damage Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/chronic-brain-damage-market

 

Chronic Brain Damage Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Chronic Brain Damage Epidemiology Segmentation:

The Chronic Brain Damage market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Chronic Brain Damage

  • Prevalent Cases of Chronic Brain Damage by severity

  • Gender-specific Prevalence of Chronic Brain Damage

  • Diagnosed Cases of Episodic and Chronic Chronic Brain Damage

 

Download the report to understand which factors are driving Chronic Brain Damage epidemiology trends @ Chronic Brain Damage Epidemiology Forecast

 

Chronic Brain Damage Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Brain Damage market or expected to get launched during the study period. The analysis covers Chronic Brain Damage market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Chronic Brain Damage Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Chronic Brain Damage Therapies and Key Companies

  • Autologous HB-adMSCs: Hope Biosciences

  • BOTOX®: Innopharm LLC

  • SB623 cells: SanBio, Inc.

  • Erythropoietin: Bundang CHA Hospital

  • TEV-50717: Teva Branded Pharmaceutical

  • Valbenazine: Neurocrine Biosciences

  • Sativex: Jazz Pharmaceuticals

  • florbetapir F 18: Avid Radiopharmaceuticals

  • UDI-001: Rohto Pharmaceutical

  • NT 201: Merz Pharmaceuticals

 

Discover more about therapies set to grab major Chronic Brain Damage market share @ Chronic Brain Damage Treatment Landscape

 

Chronic Brain Damage Market Drivers

  • Rising Prevalence of Neurodegenerative Diseases

  • Advancements in Neuroimaging and Diagnostic Technologies

  • Growing Research & Development

  • Increasing Awareness & Diagnosis Rates

  • Expanding Geriatric Population

  • Government & Private Funding for Brain Health

  • Emerging Stem Cell & Gene Therapies

 

Chronic Brain Damage Market Barriers

  • High Cost of Treatment & Rehabilitation

  • Lack of Curative Therapies

  • Complexity in Diagnosis & Misdiagnosis Issues

  • Limited Insurance Coverage

  • Regulatory Challenges in Drug Approval

  • Ethical Concerns in Stem Cell Therapy

  • Shortage of Skilled Neurologists & Healthcare Infrastructure

 

Scope of the Chronic Brain Damage Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Chronic Brain Damage Companies: Hope Biosciences, Innopharm LLC, SanBio, Inc., Bundang CHA Hospital, Teva Branded Pharmaceutical, Neurocrine Biosciences, Jazz Pharmaceuticals, Avid Radiopharmaceuticals, Rohto Pharmaceutical, Merz Pharmaceuticals, and others

  • Key Chronic Brain Damage Therapies: Autologous HB-adMSCs, BOTOX®, SB623 cells, Erythropoietin, TEV-50717, Valbenazine, Sativex, florbetapir F 18, UDI-001, NT 201, and others

  • Chronic Brain Damage Therapeutic Assessment: Chronic Brain Damage current marketed and Chronic Brain Damage emerging therapies

  • Chronic Brain Damage Market Dynamics: Chronic Brain Damage market drivers and Chronic Brain Damage market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Chronic Brain Damage Unmet Needs, KOL’s views, Analyst’s views, Chronic Brain Damage Market Access and Reimbursement

 

To know more about Chronic Brain Damage companies working in the treatment market, visit @ Chronic Brain Damage Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Chronic Brain Damage Market Report Introduction

2. Executive Summary for Chronic Brain Damage

3. SWOT analysis of Chronic Brain Damage

4. Chronic Brain Damage Patient Share (%) Overview at a Glance

5. Chronic Brain Damage Market Overview at a Glance

6. Chronic Brain Damage Disease Background and Overview

7. Chronic Brain Damage Epidemiology and Patient Population

8. Country-Specific Patient Population of Chronic Brain Damage

9. Chronic Brain Damage Current Treatment and Medical Practices

10. Chronic Brain Damage Unmet Needs

11. Chronic Brain Damage Emerging Therapies

12. Chronic Brain Damage Market Outlook

13. Country-Wise Chronic Brain Damage Market Analysis (2019–2032)

14. Chronic Brain Damage Market Access and Reimbursement of Therapies

15. Chronic Brain Damage Market Drivers

16. Chronic Brain Damage Market Barriers

17. Chronic Brain Damage Appendix

18. Chronic Brain Damage Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Brain Damage Market Revenue to Expand Significantly by 2032, States DelveInsight Report | Hope Biosciences, Innopharm LLC, SanBio, Rohto Pharma, Teva Branded Pharma

Epilepsy Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | ES Therapeutics, PhytoTech Therapeutics, Ltd., UCB Biopharma, SK Life Science, UCB Biopharma

The Key Epilepsy Companies in the market include – Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Jazz Pharmaceuticals, SK Biopharmaceutical, Angelini Pharma/Ono Pharmaceutical, Novartis, Xenon Pharmaceuticals, Takeda, Ovid Therapeutics, Biohaven Pharmaceuticals/Knopp Biosciences, and others.

 

DelveInsight’s “Epilepsy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Epilepsy, historical and forecasted epidemiology as well as the Epilepsy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Epilepsy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Epilepsy Market Forecast

 

Some of the key facts of the Epilepsy Market Report:

  • The Epilepsy market size was valued ~USD 9 billion in 2023 and is anticipated to grow with a significant CAGR of 7% during the study period (2020-2034)

  • In March 2025, QurAlis Corporation, a clinical-stage biotechnology company focused on developing precision medicines for neurodegenerative and neurological diseases, announced positive topline results from its Phase 1 proof-of-mechanism (PoM) clinical trial of QRL-101. The study, conducted in healthy volunteers, assessed biomarkers associated with amyotrophic lateral sclerosis (ALS) and epilepsy.

  • In November 2024, uniQure N.V. (NASDAQ: QURE), a pioneering gene therapy company focused on developing treatments for severe medical conditions, has announced that the first patient has been administered AMT-260 in the GenTLE Phase I/IIa clinical trial for refractory mesial temporal lobe epilepsy (MTLE).

  • In September 2024, Synergia Medical successfully implanted its neurostimulation technology in the first two patients participating in a study aimed at treating epilepsy. These procedures are part of a first-in-human trial being conducted at two locations in Belgium and one in Germany. The surgeries for the initial patients were performed earlier this month at the Belgian sites, according to the company.

  • In 2023, the Epilepsy Treatment Market in the US was valued at around USD 4.3 billion, representing approximately 48% of the total market revenue across the 7MM.

  • In 2023, the Epilepsy Treatment Market in the EU4 and the UK held a market share of approximately 29%. Among these countries, Germany had the largest market share, followed by France and the UK. These figures are expected to evolve during the forecast period.

  • In 2023, the Epilepsy Treatment Market Size in Japan was estimated to be around USD 2.1 billion.

  • In 2023, the total diagnosed prevalent cases of epilepsy in the 7MM were approximately 7 million, with an expected compound annual growth rate (CAGR) of 0.4% through 2034.

  • In 2023, the US had around 3.3 million total diagnosed epilepsy cases, with 14% of them in children and 86% in adults. The total number of epilepsy cases is anticipated to rise by 2034.

  • In 2023, the EU4 and the UK had approximately 1.3 million male cases and 1.5 million female cases of diagnosed epilepsy, with these figures expected to increase over the study period.

  • In 2023, Germany reported the highest number of epilepsy cases among the EU4 and the UK, with approximately 735 thousand cases. Of these, nearly 74% were focal seizures, 18% were generalized seizures, and 8% were classified as other determined or undetermined epileptic seizures.

  • In 2023, Japan had the second-highest number of diagnosed epilepsy cases among the 7MM, with approximately 890 thousand cases. These numbers are anticipated to change over the course of the study period.

  • In Japan, drug-resistant epilepsy/refractory cases accounted for the highest number of epilepsy cases, with approximately 82 thousand in 2023, followed by photosensitivity and childhood absence epilepsy, each with 44 thousand cases. These figures are projected to change by 2034.

  • The epilepsy market is expected to experience steady growth, with a compound annual growth rate (CAGR) of around 7% projected from 2024 to 2034. This growth across the 7MM will be fueled by the launch of new therapies, including LIBERVANT (diazepam buccal film), XEN1101, COMFYDE (carisbamate), Lorcaserin (E2023), and Soticlestat (TAK-935), among others.

  • DelveInsight estimates that in 2023, there were around 7 million total diagnosed prevalent cases of epilepsy across the 7MM. Of these, 48% of the cases were in the US, 39% were in the EU4 and the UK, and 13% were in Japan.

  • Key Epilepsy Companies: Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Jazz Pharmaceuticals, SK Biopharmaceutical, Angelini Pharma/Ono Pharmaceutical, Novartis, Xenon Pharmaceuticals, Takeda, Ovid Therapeutics, Biohaven Pharmaceuticals/Knopp Biosciences, and others

  • Key Epilepsy Therapies: LIBERVANT (diazepam buccal film), EPIDIOLEX/EPIDYOLEX (cannabidiol), XCOPRI/ONTOZRY (cenobamate), AFINITOR DISPERZ/VOTUBIA (everolimus), XEN1101/Azetukalner, Soticlestat (TAK-935), BHV-7000 (KB-3061), and others

  • The Epilepsy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Epilepsy pipeline products will significantly revolutionize the Epilepsy market dynamics.

 

Epilepsy Overview

Epilepsy is a neurological disorder characterized by recurrent, unprovoked seizures caused by abnormal electrical activity in the brain. Seizures can vary in severity and may involve changes in behavior, consciousness, muscle control, or sensory perception. The condition can develop at any age and may result from various factors, including genetics, brain injury, infections, or structural brain abnormalities. Epilepsy is typically managed with medication, lifestyle adjustments, and sometimes surgery for more severe cases.

 

Get a Free sample for the Epilepsy Market Report

https://www.delveinsight.com/report-store/epilepsy-market

 

Epilepsy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Epilepsy Epidemiology Segmentation:

The Epilepsy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Epilepsy

  • Prevalent Cases of Epilepsy by severity

  • Gender-specific Prevalence of Epilepsy

  • Diagnosed Cases of Episodic and Chronic Epilepsy

 

Download the report to understand which factors are driving Epilepsy epidemiology trends @ Epilepsy Epidemiology Forecast

 

Epilepsy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Epilepsy market or expected to get launched during the study period. The analysis covers Epilepsy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Epilepsy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Epilepsy Therapies and Key Companies

  • LIBERVANT (diazepam buccal film): Aquestive Therapeutics/Atnahs Pharma (Pharmanovia)

  • EPIDIOLEX/EPIDYOLEX (cannabidiol): Jazz Pharmaceuticals

  • XCOPRI/ONTOZRY (cenobamate): SK Biopharmaceutical/Angelini Pharma/Ono Pharmaceutical

  • AFINITOR DISPERZ/VOTUBIA (everolimus): Novartis

  • XEN1101/Azetukalner: Xenon Pharmaceuticals

  • Soticlestat (TAK-935): Takeda/Ovid Therapeutics

  • BHV-7000 (KB-3061): Biohaven Pharmaceuticals/Knopp Biosciences

 

Discover more about therapies set to grab major Epilepsy market share @ Epilepsy Treatment Market

 

Epilepsy Market Strengths

  • Growing Focus On Providing Seizure-Free Life To Fuel Innovations.

  • Growth in The Demand For Epileptic Seizures Treatment

 

Epilepsy Market Opportunities

  • Growing funding for R&D of epilepsy is also contributing as a factor for the market growth.

  • Rising neurological diseases among population will also propel the growth of the market Increasing brain injuries cases due to road accidents will also drive the growth of this market

 

Scope of the Epilepsy Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Epilepsy Companies: Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Jazz Pharmaceuticals, SK Biopharmaceutical, Angelini Pharma/Ono Pharmaceutical, Novartis, Xenon Pharmaceuticals, Takeda, Ovid Therapeutics, Biohaven Pharmaceuticals/Knopp Biosciences, and others

  • Key Epilepsy Therapies: LIBERVANT (diazepam buccal film), EPIDIOLEX/EPIDYOLEX (cannabidiol), XCOPRI/ONTOZRY (cenobamate), AFINITOR DISPERZ/VOTUBIA (everolimus), XEN1101/Azetukalner, Soticlestat (TAK-935), BHV-7000 (KB-3061), and others

  • Epilepsy Therapeutic Assessment: Epilepsy current marketed and Epilepsy emerging therapies

  • Epilepsy Market Dynamics: Epilepsy market drivers and Epilepsy market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Epilepsy Unmet Needs, KOL’s views, Analyst’s views, Epilepsy Market Access and Reimbursement

 

To know more about Epilepsy companies working in the treatment market, visit @ Epilepsy Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Epilepsy Market Report Introduction

2. Executive Summary for Epilepsy

3. SWOT analysis of Epilepsy

4. Epilepsy Patient Share (%) Overview at a Glance

5. Epilepsy Market Overview at a Glance

6. Epilepsy Disease Background and Overview

7. Epilepsy Epidemiology and Patient Population

8. Country-Specific Patient Population of Epilepsy

9. Epilepsy Current Treatment and Medical Practices

10. Epilepsy Unmet Needs

11. Epilepsy Emerging Therapies

12. Epilepsy Market Outlook

13. Country-Wise Epilepsy Market Analysis (2020–2034)

14. Epilepsy Market Access and Reimbursement of Therapies

15. Epilepsy Market Drivers

16. Epilepsy Market Barriers

17. Epilepsy Appendix

18. Epilepsy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Epilepsy Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | ES Therapeutics, PhytoTech Therapeutics, Ltd., UCB Biopharma, SK Life Science, UCB Biopharma

Skye Bellarmine’s Escaping Solace Achieves #1 International Best-Selling Status Within Hours of Launch

Skye Bellarmine’s Escaping Solace Achieves #1 International Best-Selling Status Within Hours of Launch

Life’s not about What happens to you, but rather What You Do with what happens to you.
Escaping Solace by Skye Bellarmine achieves #1 International Best-Selling Status within 15 hours of launch.

Skye Bellarmine, acclaimed author of the Breaking Solace trilogy, captured her readers’ attention again with her second book, Escaping Solace. Within 15 hours of launch, it achieved #1 International Best-Selling Status, resonating with readers affected by narcissistic abuse. The book reached Best-Selling Status in the U.S., Canada, Spain, and France, topping 46 categories, including five #1 rankings.

“Escaping Solace explores the harsh truths of abusive relationships, illuminating the impact of narcissistic personality disorder and the damaging cycles that ensnare victims in unhealthy dynamics,” says the author Skye Bellarmine. “My work is not just a gripping narrative. I believe it serves as a guide for healing and empowerment, empowering readers to regain their self-worth and freedom.”

In Escaping Solace, Tali Solace, the main character of the trilogy, decides to divorce her charming yet manipulative husband, Blake. However, she soon discovers that leaving a narcissistic partner is not simply a matter of walking away. Blake excels at manipulation and control, exploiting Tali’s empathetic and gentle nature. As Tali commits to her freedom, she must learn to outmaneuver his deceitful tactics to protect herself and regain control of her life.

The story exposes the disturbing characteristics of narcissistic personality disorder, such as:

  • A deep sense of entitlement and superiority, where the narcissist’s truth is the only truth.
  • Calculated and passive-aggressive behaviors, often disguised as impulsive or irrational actions.
  • Deceptive manipulation causes victims to question their own reality until they feel completely trapped.

Through Tali’s heartfelt journal entries addressed to “Dear Josie”, readers witness her internal battle as she grapples with self-doubt, emotional trauma, and the desire to reclaim her identity. Simultaneously, the book offers chilling insight into Blake’s mind, showcasing the dark, calculated nature of narcissistic behavior and the relentless pursuit of control.

Bellarmine’s personal experiences have deeply influenced the message of Escaping Solace. After navigating a challenging marriage with a narcissistic partner, she fully grasps the intricacies involved in leaving an abusive relationship.

She underscores that breaking free from a manipulative abuser is not a mark of weakness, but rather a courageous act — one that can pave the way for healing, self-discovery, and eventual liberation.

Skye Bellarmine’s mission goes beyond merely telling stories. At Star Skye Press LLC, she commits to assisting victims of abusive relationships in restoring their self-worth and resilience. The publishing house seeks to elevate tales of hope, strength, and empowerment, inspiring survivors to reshape their narratives and escape toxic cycles.

Alongside her healing journey from narcissistic abuse, Bellarmine found motivation in a transformative personal incident. She was involved in a head-on crash with a wrong-way driver, which resulted in a seven-day coma and bleak survival chances.

Against all odds, Bellarmine exceeded expectations, undergoing 12 surgeries over six years to regain her ability to walk and use her arm. This extraordinary journey of physical and emotional recovery has bolstered her unwavering commitment to helping others confront challenges.

Bellarmine is working on the third and final installment of the Breaking Solace trilogy. The upcoming book promises to explore life after narcissistic abuse in greater depth, addressing the challenges of rebuilding one’s life, fostering healthy relationships, and embracing self-worth.

Escaping Solace is now available on Amazon, offering a lifeline of hope to anyone trapped in the grasp of narcissistic abuse. Readers seeking strength, clarity, and guidance will find a powerful companion in Tali’s story.

Bellarmine’s message is clear: You are worthy, enough, and meant to shine.

For more information about Skye Bellarmine, Escaping Solace, or upcoming releases, visit www.StarSkyePress.com

About Skye Bellarmine

Skye Bellarmine is an author committed to empowering individuals to overcome abuse and reclaim their strength. Raised in a nomadic family, she adapted to diverse environments, developing empathy and resilience. Through her writing, Skye inspires others to overcome challenges and embrace their worth. Her debut book, Breaking Solace, reflects her mission to help readers escape toxic relationships, find inner strength, and rebuild their lives.

Media Contact
Company Name: Star Skye Press LLC
Contact Person: Skye Bellarmine, Author, Breaking Solace and Escaping Solace
Email: Send Email
Country: United States
Website: https://starskyepress.com/

Premium Garage Doors from Europe: Ryterna Names Calgary Garage Door Fix Exclusive Canadian Distributor

Premium Garage Doors from Europe: Ryterna Names Calgary Garage Door Fix Exclusive Canadian Distributor
With over 2,200 5-star Google reviews, family-owned and operated business Calgary Garage Door Fix has emerged as Canada’s best-rated garage door company.

Calgary Garage Door Fix, Canada’s best-rated garage door business, has been appointed the exclusive distributor of Ryterna garage doors in Canada. This partnership with one of Europe’s largest premium garage door manufacturers offers residents and businesses access to unique, fully customizable garage doors in Calgary.

Calgary Garage Door Fix has built a reputation as the go-to provider for garage door services in Calgary. From installations and repairs to maintenance and customization, the company has consistently delivered top-notch service, earning it the title of Canada’s best-rated garage door business. Partnering with a globally recognized brand further solidifies its position as a leader in the industry.

Ryterna has long been a leading name in the European garage door industry. With Calgary Garage Door Fix now serving as its sole Canadian distributor, customers in Calgary and beyond can experience the exceptional durability, aesthetics, and functionality that Ryterna garage doors are known for.

“We are thrilled to partner with Ryterna and offer their exceptional garage doors to our customers. This partnership allows us to provide Calgarians with access to world-class products that combine beauty, functionality, and durability,” said Calgary Garage Door Fix owner Stan Klugman.

Renowned for their innovative designs and high-quality craftsmanship, Ryterna garage doors stand out for their fully customizable options, catering to residential and industrial needs. Homeowners in Calgary can now choose from various styles, materials, and finishes to create garage doors that perfectly complement their property’s architecture. Whether a modern minimalist design or a classic wooden finish, Ryterna offers solutions that blend seamlessly with any aesthetic.

For its industrial clients, Ryterna provides robust, high-performance garage doors designed to withstand heavy use and extreme weather conditions. These doors are engineered with advanced security features, ensuring optimal protection for commercial properties.

With the addition of Ryterna garage doors to its portfolio, Calgary Garage Door Fix now offers customers in Calgary access to premium garage doors that combine European elegance with unmatched durability. For those looking to upgrade their garage doors, the company offers free consultations to help customers choose the perfect Ryterna door.

For more information, visit https://www.calgarygaragedoorfix.com/residential-garage-doors-calgary/

With its headquarters in Calgary, Alberta, Calgary Garage Door Fix is well-positioned to serve residential and commercial clients across the region. The company’s team of skilled technicians ensures that every installation, repair, or maintenance service is completed to the highest standards.

Calgary Garage Door Fix’s commitment to quality is evident with its flagship Ryterna products, manufactured using state-of-the-art techniques and high-grade materials to ensure its garage doors meet the highest standards. Each door is designed to provide superior insulation, noise reduction, and energy efficiency, making it an ideal choice for the region’s diverse climate.

“All Ryterna garage doors we offer come with the best in the industry warranty – up to 10 years depending on the model. All other garage door manufacturers offer springs rated for 10,000 cycles, but Ryterna doors come standard with 25,000 cycle springs with an option to upgrade to 100,000 cycle springs which are guaranteed for life for residential use,” said Klugman.

Additionally, Ryterna garage doors are fully customizable, offering over 100 panel styles, designs, and colors, so no two garage doors look alike. From sectional and side-sliding doors to carriage-style garage doors, Calgary Garage Door Fix sets a new benchmark for quality and customization.

Calgary Garage Door Fix’s exclusive distribution of Ryterna garage doors marks a significant milestone for the Canadian garage door industry, redefining what customers can expect from their garage doors. The collaboration between Calgary Garage Door Fix and Ryterna is a testament to both companies’ dedication to excellence.

About the Company:

Calgary Garage Door Fix is Canada’s best-rated garage door business, specializing in residential and industrial garage door installations, repairs, and maintenance. Based in Calgary, Alberta, the company is now the exclusive Canadian distributor for Ryterna, one of Europe’s largest premium garage door manufacturers. Known for its fully customizable, high-quality garage doors, Ryterna offers innovative designs that combine durability, aesthetics, and advanced functionality. Calgary Garage Door Fix’s commitment to excellence and customer satisfaction has made it a trusted name in the industry.

Media Contact
Company Name: Calgary Garage Door Fix
Contact Person: Stan Klugman
Email: Send Email
Phone: (403) 990-9536
Address:4407 116 Ave SE #6
City: Calgary
State: AB
Country: Canada
Website: https://www.calgarygaragedoorfix.com/residential-garage-doors-calgary/

The Magic of a Moment by Gary Fretwell Achieves #1 International Best-Selling Status

The Magic of a Moment by Gary Fretwell Achieves #1 International Best-Selling Status

Life is a great adventure, endeavor to live it fully.
Acclaimed life coach, consultant, and speaker Gary Fretwell has reached a remarkable milestone that speaks volumes about his passion for inspiring others. His debut book, *The Magic of a Moment*, has shot straight to the top, achieving #1 Best-Selling and International Best-Selling Status within just eight hours of its launch, dominating the charts in both the United States and Canada.

“I am absolutely thrilled to share that The Magic of a Moment has become the #1 International Best-Seller,” proclaimed Fretwell, the proud author. “The book has secured Best-Selling Status in an impressive 27 categories, with two categories achieving #1 rankings. By the 13th hour post-launch, it also claimed #1 International Best-Selling Status — an extraordinary feat for my debut effort.”

The Magic of a Moment offers a transformative narrative designed to help readers unlock the hidden power within everyday moments and pursue their wildest dreams. Fretwell masterfully combines practical inspiration with actionable steps, urging readers to seize opportunities and cultivate a results-oriented mindset. Through relatable storytelling, he illustrates how to recognize limitless possibilities, empowering individuals to take decisive steps toward fulfillment.

As the founder of Fretwell Solutions, Fretwell brings a wealth of experience. During his career he worked with over 1,000 institutions benefiting from his expertise both as an administrator and consultant. He has spoken on critical topics including leadership, marketing, strategic planning, organizational change, and productivity. His dynamic style has helped countless individuals and organizations overcome barriers to success, both in the U.S. and around the globe.

The Magic of a Moment is not just a book; it embodies Fretwell’s mission to inspire individuals to unlock their potential and drive meaningful growth. It also underscores the importance of sharing our knowledge and gifts with others.

Fretwell’s personal journey of overcoming childhood neglect and abuse serves as a powerful catalyst for his desire to inspire. He shares a belief that resonates deeply: “It isn’t where you came from; it’s where you’re going that counts,” a sentiment echoed by the legendary Ella Fitzgerald. His story is a testament to resilience and determination.

In The Magic of a Moment, Fretwell emphasizes that true success lies in recognizing the small opportunities that surround us every day and stepping forward with confidence to foster personal and professional growth. His thoughtful insights encourage readers to continually reflect on their next actionable steps toward bringing their aspirations to life.

By cultivating a habit of consistent action, individuals can steadily progress toward their goals and transform their lives.

In addition to the book, Fretwell is excited to announce an accompanying journal designed to help readers document their insights, reflections, and action plans. This practical tool will keep readers focused and motivated as they take continuous steps toward their dreams. Furthermore, he is diligently working on his third book, further amplifying his mission to provide transformative guidance for those seeking meaningful progress.

As part of his unwavering commitment to empowering others, Fretwell delivers keynote speeches, conducts coaching sessions, and provides consulting services through Fretwell Solutions. His work is centered on helping individuals and organizations enhance productivity, strengthen leadership capabilities, and embrace transformative change.

Fretwell firmly believes that everyone possesses the power to unlock their fullest potential; they simply need to recognize and act upon the magic present in each moment.

When asked about his core message, Fretwell passionately shares, “Life is filled with untapped possibilities. The key is to take action — no matter how small — and keep moving toward your dreams. Every moment presents a new opportunity to change your life.”

The Magic of a Moment is now available for purchase on Amazon Kindle and other leading bookseller outlets. Readers seeking motivation, practical inspiration, and actionable steps to enhance their personal and professional lives can order their copy today.

For more information, www.garyfretwell.com.

About Gary Fretwell

Gary Fretwell founded Fretwell Solutions, specializing in life coaching, consulting, and speaking engagements focused on personal productivity, self-management, and leadership. With a career spanning work with over 1,000 institutions and thousands of audiences worldwide, Gary has dedicated his life to helping individuals realize their full potential. His mission is to provide practical inspiration and transformative strategies to empower individuals to achieve meaningful growth.

Media Contact
Company Name: Fretwell Solutions
Contact Person: Gary L. Fretwell
Email: Send Email
Phone: 720-984-6464
State: Arizona
Country: United States
Website: https://garyfretwell.com/

Dementia With Diabetes Market Expected to Experience Major Growth by 2032, According to DelveInsight | Novo Nordisk, Pfizer, EIP Pharma, Sun Pharma, Allyx Therapeutics, Bioxcel Therapeutics

The Key Dementia With Diabetes Companies in the market include – Novo Nordisk, Pfizer, EIP Pharma, Sun Pharma, Allyx Therapeutics, Bioxcel Therapeutics, and others.

 

DelveInsight’s “Dementia With Diabetes Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Dementia With Diabetes, historical and forecasted epidemiology as well as the Dementia With Diabetes market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Dementia With Diabetes market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dementia With Diabetes Market Forecast

 

Some of the key facts of the Dementia With Diabetes Market Report:

  • The Dementia With Diabetes market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

  • The most prevalent kind of dementia, according to the Centers for Disease Control and Prevention (2022), is Alzheimer’s disease. As of right now, estimates place the number of Americans with Alzheimer’s disease and related dementias at 5.8 million, including 5.6 million persons 65 years of age and older and roughly 200,000 people under 65 with younger-onset Alzheimer’s

  • Goodman et al. (2023) reported that Alzheimer’s (43.5%) was the most prevalent category, with vascular (14.5%), Lewy body (5.4%), frontotemporal (1.0%), and alcohol-induced (0.7%) following closely behind. In the US, the prevalence of other diagnosed forms of dementia was 0.2%

  • Over 900,000 people in the UK are thought to have dementia, according to Dementia UK (2023).

  • Reinke et al. (2022) reported that a cohort study using German health claims data revealed that the risk of dementia fell by 26% after a year of type 2 diabetes diagnosis, reaching a lowest at 4.75 years, and then increased until the conclusion of the follow-up.

  • Key Dementia With Diabetes Companies: Novo Nordisk, Pfizer, EIP Pharma, Sun Pharma, Allyx Therapeutics, Bioxcel Therapeutics, and others

  • Key Dementia With Diabetes Therapies: Thiazolidinediones, Meglitinides, GLP-1 receptor agonists, DPP-4 inhibitors, and others

  • The Dementia With Diabetes market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dementia With Diabetes pipeline products will significantly revolutionize the Dementia With Diabetes market dynamics.

 

Dementia With Diabetes Overview

Dementia with diabetes” refers to the condition where individuals with diabetes develop dementia, a general term for a decline in cognitive ability severe enough to interfere with daily life. Diabetes can increase the risk of developing various types of dementia, including Alzheimer’s disease and vascular dementia.

 

Get a Free sample for the Dementia With Diabetes Market Report

https://www.delveinsight.com/report-store/dementia-with-diabetes-market-forecast

 

Dementia With Diabetes Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Dementia With Diabetes Epidemiology Segmentation:

The Dementia With Diabetes market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Dementia With Diabetes

  • Prevalent Cases of Dementia With Diabetes by severity

  • Gender-specific Prevalence of Dementia With Diabetes

  • Diagnosed Cases of Episodic and Chronic Dementia With Diabetes

 

Download the report to understand which factors are driving Dementia With Diabetes epidemiology trends @ Dementia With Diabetes Epidemiology Forecast

 

Dementia With Diabetes Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dementia With Diabetes market or expected to get launched during the study period. The analysis covers Dementia With Diabetes market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Dementia With Diabetes Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Key Dementia with DiabetesTherapies and Companies:

  • Thiazolidinediones: Novo Nordisk

  • Meglitinides: Pfizer

  • GLP-1 receptor agonists: EIP Pharma

  • DPP-4 inhibitors: Sun Pharma

 

Discover more about therapies set to grab major Dementia With Diabetes market share @ Dementia With Diabetes Treatment Market

 

Dementia With Diabetes Market Unmet Needs

  • Lack of epidemiological data

  • Early detection and diagnosis

  • Scarcity of approved therapies and challenges in treatment

  • Integrated Care Approach

  • Impact on quality of life

 

Scope of the Dementia With Diabetes Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Dementia With Diabetes Companies: Novo Nordisk, Pfizer, EIP Pharma, Sun Pharma, Allyx Therapeutics, Bioxcel Therapeutics, and others

  • Key Dementia With Diabetes Therapies: Thiazolidinediones, Meglitinides, GLP-1 receptor agonists, DPP-4 inhibitors, and others

  • Dementia With Diabetes Therapeutic Assessment: Dementia With Diabetes current marketed and Dementia With Diabetes emerging therapies

  • Dementia With Diabetes Market Dynamics: Dementia With Diabetes market drivers and Dementia With Diabetes market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Dementia With Diabetes Unmet Needs, KOL’s views, Analyst’s views, Dementia With Diabetes Market Access and Reimbursement

 

To know more about Dementia With Diabetes companies working in the treatment market, visit @ Dementia With Diabetes Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Dementia With Diabetes Market Report Introduction

2. Executive Summary for Dementia With Diabetes

3. SWOT analysis of Dementia With Diabetes

4. Dementia With Diabetes Patient Share (%) Overview at a Glance

5. Dementia With Diabetes Market Overview at a Glance

6. Dementia With Diabetes Disease Background and Overview

7. Dementia With Diabetes Epidemiology and Patient Population

8. Country-Specific Patient Population of Dementia With Diabetes

9. Dementia With Diabetes Current Treatment and Medical Practices

10. Dementia With Diabetes Unmet Needs

11. Dementia With Diabetes Emerging Therapies

12. Dementia With Diabetes Market Outlook

13. Country-Wise Dementia With Diabetes Market Analysis (2019–2032)

14. Dementia With Diabetes Market Access and Reimbursement of Therapies

15. Dementia With Diabetes Market Drivers

16. Dementia With Diabetes Market Barriers

17. Dementia With Diabetes Appendix

18. Dementia With Diabetes Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dementia With Diabetes Market Expected to Experience Major Growth by 2032, According to DelveInsight | Novo Nordisk, Pfizer, EIP Pharma, Sun Pharma, Allyx Therapeutics, Bioxcel Therapeutics

Invest In A Home’s Comfort With Carrier Systems from a Reputable Montana HVAC Company

Invest In A Home's Comfort With Carrier Systems from a Reputable Montana HVAC Company

Bozeman, MT – Since 1999, Comfort Systems of Montana has been a trusted name in providing reliable heating and cooling solutions to Bozeman, Montana, and the surrounding communities. As a Veteran-Owned and Operated Local Family Business, Comfort Systems of Montana is proud to deliver high-quality services with a phenomenal team of licensed professionals dedicated to designing, installing, and servicing both residential and commercial HVAC systems.

What sets Comfort Systems of Montana apart is its distinction as the only Factory Authorized Carrier Dealer in the area. This accreditation highlights their unwavering commitment to excellence, ensuring customers receive the best HVAC systems on the market. Carrier, a global leader in home heating and cooling solutions, entrusts only the most qualified dealers with its Factory Authorized designation. Customers can expect superior service, cutting-edge technology, and peace of mind when they choose a Carrier Factory Authorized Dealer.

Choosing Comfort Systems of Montana means working with highly trained, specialized technicians who exclusively service Carrier products. This expertise ensures that every installation, repair, or maintenance service is handled with precision. Furthermore, should any part of your HVAC system require replacement, Comfort Systems of Montana’s team ensures that eligible Carrier systems will be fully supported and honored by Carrier’s extensive dealer network. This guarantees customers long-term reliability and protection for their investment.

A standout benefit of working with a Carrier Factory Authorized Dealer like Comfort Systems of Montana is their ongoing participation in Carrier Corporation’s training programs. These regular training sessions keep their technicians up to date on the latest HVAC products, technology advancements, and industry best practices. For customers, this translates to unparalleled service quality and the assurance that their system will operate efficiently and effectively for years to come.

Comfort Systems of Montana’s commitment to excellence extends beyond the technical aspects of HVAC services. As a local business rooted in the community, they prioritize building long-lasting relationships with their customers. Whether you need a routine HVAC maintenance check, a new system installation, or specialized repairs, their team is ready to provide reliable solutions tailored to your unique needs.

To learn the ins and outs of your HVAC system and discover tips for maintaining your home’s comfort year-round, check out Comfort Systems of Montana’s blog. Their team shares expert advice and insights to help you make the most of your heating and cooling systems.

Looking to upgrade your home’s cooling capabilities? Comfort Systems of Montana specializes in air conditioning services that enhance energy efficiency and overall comfort. From installing cutting-edge Carrier systems to maintaining existing units, their expertise ensures you’ll enjoy a cooler home during Montana’s warm summer months.

For more information about Comfort Systems of Montana and their trusted services, visit their website at Comfort Systems of Montana. You can also email info@comfortsystemsofmt.com or visit their office at 125 Central Ave Unit #1J, Bozeman, MT 59718.

Experience the difference of working with a local, veteran-owned HVAC company committed to providing top-notch solutions for your home or business. Comfort Systems of Montana is ready to help you invest in your comfort and peace of mind today.

Media Contact
Company Name: Comfort Systems of Montana
Contact Person: Michael Boston
Email: Send Email
Phone: 406-333-1927
Address:125 Central Ave Unit #1J
City: Bozeman
State: MT 59718
Country: United States
Website: https://comfortsystemsofmt.com/

Art PR Agency JPR Media Group works with Hélène de Beauvoir exhibition at Amar Gallery

London, UK – 18 March, 2025 – Top Art PR agency JPR Media Group delivers art press coverage for the Hélène de Beauvoir: The Woman Destroyed exhibition at Amar Gallery.

Amar Gallery’s exhibition Hélène de Beauvoir: The Woman Destroyed, is the first ever solo exhibition of Hélène de Beauvoir’s work in London. Often overshadowed by her older sister, the writer Simone de Beauvoir, this exhibition features paintings & works on paper from the 1950s to 1980s. Amar Gallery’s founder, Amar Singh, was recently described by The Telegraph as a “farsighted art dealer” for consistently discovering overlooked artists and being the first gallerist to show the work of Lynne Drexler in London. The Woman Destroyed is an exhibition which took Singh three years to put together, sourcing works from around the world, meeting patrons of de Beauvoir and discovering how important Hélène de Beauvoir was to her sister and the global feminist movement.

Editor Annalisa Tacoli notes Picasso was an admirer of Hélène’s paintings. Picasso became familiar with de Beauvoir’s work when the artist had her first solo exhibition in Paris in 1936 at Galerie Jacques Bonjean, a gallery cofounded by Christian Dior, who began his career as an art dealer before becoming a fashion powerhouse. Galerie Bonjean also exhibited the work of Picasso, Braque, Dali and much like Hélène even gave Leonor Fini her first solo exhibition.

In Tout compte fait (1972), one of Simone de Beauvoir’s autobiographical works, she wrote collaborating with Hélène was something she had long wished for. In 1967 one and forty-three first edition copies of Simone de Beauvoir’s The Woman Destroyed were published by Gallimard with sixteen etchings by Hélène. First editions of this book are extremely rare, and one copy is on view at Amar Gallery. This incredibly important book in feminist ideology was the first time the de Beauvoir sisters collaborated together. Publisher Gallimard was afraid that the publication of such ‘feminine’ 3 literature would give it the mark of a publisher intent on overturning the social order.

The main themes covered in Simone de Beauvoir’s The Woman Destroyed are echoed in the individual memoirs of the de Beauvoir sisters, with particular regard to their mother’s confined domestic life in their family home in the rue de Rennes, Paris, and Simone’s later experience as the second woman in her relationship with philosopher, novelist and political activist Jean-Paul Sartre.

Referring to her sister, Hélène wrote, “I was her first reader…and I would draw” in her book Souvenirs, where she recalls how, in the early years, she came to choose the vocation of artist, whilst her elder sister preferred to write.

In 1964, Sartre was awarded the Nobel prize in literature which he rejected as he did not wish to be “transformed” by such an award. After rejecting the award Sartre tried to escape the media by hiding in the house of Hélène in Goxwiller, Alsace. Sartre and Simone de Beauvoir remained close with Hélène, regularly attending her exhibitions and immersing her with their electric circle including Cocteau, and Lionel de Roulet, whom Hélène married.

Claudine Monteil, former French diplomat and women’s rights specialist, presented a special talk at Amar Gallery about her relationship with both Simone and Hélène de Beauvoir. Claudine details in her book The Beauvoir Sisters, that the two sisters shared a close bond and artistic influence on one another, but also about the jealousy and rivalry. Monteil also highlights how these two remarkable women came together to help launch the modern women’s movement and make a mark on the world.

HÉLÈNE DE BEAUVOUR IN SELECTED COLLECTIONS & MUSEUMS

Centre Pompidou

Uffizi Museum Florence

Oxford University

Musée Würth France Erstein

Museum of modern and contemporary art of the City of Strasbourg

The royal library of the Netherlands

PR CONTACT:

JPR Media Group

www.jprmediagroup.com

jessica@jprmediagroup.com

m: +44(0)7950977765

JPR Media Group secured top art press coverage in UK, France, and USA newspapers and magazines in both print and online.

Media Contact
Company Name: JPR Media Group Ltd
Contact Person: Jessica Patterson
Email: Send Email
Phone: 07950977765
Address:14th Floor 33 Cavendish Square
City: London
State: Greater London
Country: United Kingdom
Website: https://www.jprmediagroup.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Art PR Agency JPR Media Group works with Hélène de Beauvoir exhibition at Amar Gallery

Realtor Agent in San Diego, CA, Unveils Personalized Luxury Real Estate Services Amid Competitive Market Trends

Chase Penrose is proud to announce the launch of his newly refined luxury real estate services amid an evolving competitive market. With a steadfast commitment to excellence and client satisfaction, his firm is dedicated to offering tailored strategies that meet the distinct needs of San Diego’s discerning property buyers and sellers. This new initiative reflects his passion for innovative, personalized service in every transaction.

Built on a rich legacy of over a decade in the real estate industry, the business has continually raised the bar for service in the San Diego market. Starting at the age of 16 and earning his license in 2017, Chase’s early immersion in top-tier real estate environments has honed his expertise. His background in luxury residential transactions forms the foundation of a client-focused approach that drives success in today’s dynamic market.

Leveraging cutting-edge marketing techniques and bespoke service, Chase Penrose has refined his approach to luxury property transactions. Clients enjoy a seamless experience, supported by strategic planning and personalized attention throughout the process. As a trusted real estate listing agent in San Diego, CA, his innovative methods consistently yield outstanding results.

Emphasizing deep market insights and a keen eye for property potential, his team highlights each listing’s unique appeal. Through a blend of technology and hands-on expertise, every asset is showcased to its fullest potential. Recognized for his strategic approach as a real estate selling agent in San Diego, CA, Chase and his team elevate the standard of luxury property marketing.

Chase Penrose distinguishes himself with a client-first philosophy and an impressive track record in high-end real estate. His creative problem-solving and local market expertise have fostered strong, lasting relationships. “My mission is to ensure every client feels supported throughout their journey,” Chase Penrose affirms, underscoring his commitment as a dedicated Realtor agent in San Diego, CA.

As the luxury real estate landscape evolves, innovative strategies remain key to success. Prospective clients are invited to experience a seamless, personalized journey in property transactions. Discover unparalleled service from a trusted San Diego, CA Realtor by visiting https://www.chasepenrose.com today.

Media Contact
Company Name: Chase Penrose – Top Realtor in San Diego, CA
Contact Person: Chase Penrose
Email: Send Email
Phone: +1 858-900-3433
Address:8889 Rio San Diego Dr, Ste 200
City: San Diego
State: California 92108
Country: United States
Website: https://www.chasepenrose.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Realtor Agent in San Diego, CA, Unveils Personalized Luxury Real Estate Services Amid Competitive Market Trends

Long Distance Movers in Hoboken, NJ, Set New Standard With Personalized Moving Plans and White-Glove Service

HOBOKEN, NJ – Moving to a new home, whether across the state or across the country, can be a daunting process. That’s why Ample Moving is setting a new standard for seamless, stress-free moves with white-glove service and fully customized moving plans.

Ample Moving specializes in full-service packing and unpacking, furniture disassembly and reassembly, and expert handling of fragile items. Their professional team ensures that every aspect of the move is carefully managed, offering an unparalleled level of service to homeowners.

With a growing demand for high-quality relocation services, Ample Moving has established itself as the go-to long distance movers in Hoboken, NJ. By creating tailored moving plans for each client, they ensure that every relocation stays on schedule and within budget.

As part of their comprehensive services, they also offer specialized solutions for fragile and high-value items, including antiques and pianos. Clients searching for reliable residential moving services in Hoboken, New Jersey can trust Ample Moving’s expertise in handling even the most delicate belongings with care.

“Our goal is to remove the stress from moving by offering a premium experience that covers every detail,” said Andy Novak, strategy consultant. “From personalized plans to secure transportation, we ensure that our clients receive the highest level of care.”

In addition to their hands-on services, Ample Moving provides eco-friendly moving solutions, using sustainable packing materials and minimizing waste. Homeowners looking for packing and moving companies in Hoboken, New Jersey will appreciate the company’s commitment to environmentally responsible practices.

Beyond their moving services, Ample Moving offers secure storage options for short-term and long-term needs. Their climate-controlled storage facilities provide a safe space for belongings, ensuring extra convenience for clients. Those in need of a trusted Hoboken, New Jersey moving company can depend on Ample Moving’s seamless approach to relocation.

For those looking for a hassle-free relocation experience, Ample Moving’s expertise and customer-first approach make them the top choice. To learn more about their moving services or to request a personalized quote, visit https://amplemoving.com today.

Media Contact
Company Name: Ample Moving
Contact Person: Media Relations
Email: Send Email
Phone: 1-201-721-5777
Address:9 Linden Ave
City: Jersey City
State: New Jersey 07305
Country: United States
Website: https://amplemoving.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Long Distance Movers in Hoboken, NJ, Set New Standard With Personalized Moving Plans and White-Glove Service